Latest: FDA Approves New Biosimilar for Oncology Treatment
Healthcare Business

Tricuspid Regurgitation Reliable Prognostic Indicator of PAH Severity

by American Journal Managed Care
0 Comments
0 Mins
Despite knowledge of the benefits of right heart hemodynamic measures for evaluating patient prognosis in the setting of pulmonary arterial hypertension (PAH), gaps remain in a defined role for tricuspid regurgitation as it relates to echocardiographic phenotype.
Tags:
American Journal Managed Care
Author

American Journal Managed Care

Previous Post
Humana and DrFirst Integrate Prescription Alerts into Clinical Workflows
Next Post
STAT+: Pharmalittle: We’re reading about FDA OK for a lung disease drug, pharma sales in China, and more
📢

Advertisement

300x250 Banner

Recent Content

COPD Biologics: Early Treatment Insights

Pulmonology • 2 hours ago

Antihypertensive Medication Guidelines

Cardiology • 4 hours ago

Juvenile Arthritis Care Transition

Rheumatology • 6 hours ago